… Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular
atrial fibrillation (… is central to achieve good anticoagulation control. Non-vitamin K antagonist …

… atrial fibrillation, … oral anticoagulant OR NOAC OR direct oral anticoagulant OR DOAC OR
apixaban OR dabigatran OR rivaroxaban OR edoxaban OR anticoagulation OR anticoagulant. …

… atrial appendage closure (LAAC) is a nonpharmacologic option for preventing cardioembolic
events in patients with atrial fibrillation (… clinical practice, direct oral anticoagulants (DOACs) …

… and bleeding in patients with atrial fibrillation (AF).1 Oral anticoagulation is associated with a
… AF recommend non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention …

… Database using keywords: “atrial fibrillation,” “dabigatran,” “… ,” “new oral anticoagulant,” “oral
factor Xa inhibitor,” and “oral … new oral anticoagulant compared to oral anticoagulation with …

… In a large cohort of patients initiating oral anticoagulants for atrial fibrillation, we found that
adherence to anticoagulation therapy was suboptimal. During a median of 1.1 years of follow‐…

… new users of oral anticoagulants (OACs) since January 2014, 7,576 warfarin users and
14,103 direct oral anticoagulant (DOAC) users were included in this study. AF = atrial fibrillation; …

… to overcome the limitations of the conventional anticoagulant drugs. However, models to …
new oral anticoagulants. This review will briefly describe the new oral anticoagulants dabigatran…

… Despite the documented effectiveness of oral anticoagulants … ) rates with oral anticoagulants
in the management of AF; the … adherence and persistence with oral anticoagulant therapy. …

… Since 2010, several non–vitamin K antagonist oral anticoagulants (NOACs) have … of atrial
fibrillation (AF)-related stroke. We examined temporal trends in choice of oral anticoagulants (…